Literature DB >> 6356861

Diagnostic relevance of humoral and cytotoxic immune reactions in primary and secondary dilated cardiomyopathy.

B Maisch, P Deeg, G Liebau, K Kochsiek.   

Abstract

Circulating muscle-specific antimyolemmal antibodies (AMLAs) were found in 18 of 61 patients with secondary dilated cardiomyopathy (DC). All 18 patients had clinical or histologic evidence of previous perimyocarditis. AMLAs were found both in patients' serum samples and bound to the sarcolemmal sheath of the autologous myocardial biopsy specimen. Only AMLAs in postmyocardiac DC induced cytolysis of vital cardiocytes in the presence of complement, whereas hepatocytes remained unaffected. Titers of AMLAs correlated with the degree of cardiocytolysis. In contrast, antiinterfibrillary antibodies were found in 49% patients with primary DC (n = 79) and in 61% of patients (n = 30) with alcoholic DC. The incidence of antifibrillary antibodies of the antimyosin type was 23 and 24%, respectively. Incidence of both antibodies increased according to the severity assessed by New York Heart Association functional classes. Circulating immune complexes assayed by a new Clq-solid phase fluorometric assay were present in 30% of patients with postmyocarditic DC only. Lymphocyte-mediated cytotoxicity against heterologous cardiac target cells (K-cell activity) was measured in 33% of patients each with primary and secondary alcoholic DC but not postmyocarditic DC. There were no blocking factors in primary but were some in alcoholic heart disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6356861     DOI: 10.1016/0002-9149(83)90535-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  36 in total

1.  Immunological features in a case of hypereosinophilic syndrome and myocarditis.

Authors:  B Maisch; L Drude; K Kochsiek
Journal:  Heart Vessels       Date:  1990       Impact factor: 2.037

Review 2.  Immunomodulating therapy in experimental myocarditis.

Authors:  A Matsumori; C Kawai
Journal:  Springer Semin Immunopathol       Date:  1989

Review 3.  Coxsackievirus infection as a trigger of cardiac autoimmunity.

Authors:  L J Wolfgram; N R Rose
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

4.  Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression.

Authors:  A L Caforio; J H Goldman; M K Baig; A J Haven; L Dalla Libera; P J Keeling; W J McKenna
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

Review 5.  Idiopathic dilated cardiomyopathy.

Authors:  A L Caforio; J T Stewart; W J McKenna
Journal:  BMJ       Date:  1990-04-07

6.  The significance of autoantibodies against the ADP/ATP carrier for the pathogenesis of myocarditis and dilated cardiomyopathy--clinical and experimental data.

Authors:  H P Schultheiss
Journal:  Springer Semin Immunopathol       Date:  1989

7.  Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.

Authors:  Ibrahim Halil Kurt; Kemal Yavuzer; Mustafa Kemal Batur
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 8.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

9.  Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Authors:  Vanessa S Cull; Emmalene J Bartlett; Cassandra M James
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

10.  Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies.

Authors:  Adita Mascaro-Blanco; Kathy Alvarez; Xichun Yu; JoAnn Lindenfeld; Leann Olansky; Timothy Lyons; David Duvall; Janet S Heuser; Albina Gosmanova; Carl J Rubenstein; Leslie T Cooper; David C Kem; Madeleine W Cunningham
Journal:  Autoimmunity       Date:  2008-09       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.